Track Dynavax Technologies Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Dynavax Technologies Corporation DVAX · Stock Open Dynavax Technologies Corporation in new tab

15.50 USD
P/E
84.93
EPS
-0.37
P/B
3.41
ROE
-7.14
Beta
0.93
Dynavax Technologies Corporation logo

Dynavax Technologies Corporation

🧾 Earnings Recap – Q3 2025

Dynavax Technologies delivered robust third quarter results, highlighted by a 13% year-over-year increase in net product revenue for HEPLISAV-B and strategic advancement in its clinical pipeline, including an exclusive license for a novel oral COVID-19 vaccine candidate.

  • HEPLISAV-B generated $90 million in net revenue, achieving a 46% market share in the U.S. adult hepatitis B vaccine market.
  • The company announced a new $100 million share repurchase program, reinforcing its commitment to shareholder value.
  • Dynavax entered into a strategic partnership with Vaxart for a Phase IIb COVID-19 oral vaccine candidate, targeting a significant unmet need in COVID-19 prevention.
  • Continued momentum in clinical pipeline advancement, with key developments in shingles and pandemic flu vaccine candidates underway.
📅
Loading chart...
Key Metrics
P/E84.93
EPS-0.37
Book Value4.55
Price to Book3.41
Debt/Equity54.15
% Insiders0.753%
Growth
Revenue Growth0.18%
Earnings Growth0.69%
Estimates
Forward P/E46.97
Forward EPS0.33

DCF valuation

Model fair value for Dynavax Technologies Corporation (DVAX)
Result
Sign in to run the valuation for DVAX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Dynavax Technologies Corporation Logo Dynavax Technologies Corporation Analysis (DVAX)

United States Health Care Official Website Stock

Is Dynavax Technologies Corporation a good investment? Dynavax Technologies Corporation (DVAX) is currently trading at 15.50 USD.

In terms of valuation, the stock trades at a P/E ratio of 84.93. This high multiple suggests investors have priced in significant future growth expectations.

Investor FAQ

Does Dynavax Technologies Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Dynavax Technologies Corporation?

Dynavax Technologies Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Exchange Ticker
NMS (United States) DVAX
FRA (Germany) DYF1.F
LSE (United Kingdom) 0IDA.L
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 10, 2014 1:10
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion